Emerging Illicit Drug "2C": A Case Report on Its Hallucinogenic and Stimulant Properties.
Marina Nasr, Brian Assadi, Brianna C Weissman, Olyvia Gleason, Jacqueline Seikunas, Manoj Puthiyathu
Cureus September 1, 2024 DOI: 10.7759/cureus.69407 via PubMed
Summary
AI-generated from the abstractA 22-year-old woman with bipolar I disorder was admitted to a psychiatric emergency department after using the illicit drug 2C, a compound with hallucinogenic and stimulant properties similar to ketamine, MDMA, methamphetamine, cocaine, and opioids. She experienced visual hallucinations, euphoria, and an increased heart rate. Laboratory tests confirmed the presence of 2C components. She required admission to an acute inpatient psychiatric unit for medication stabilization. The case highlights the need for healthcare providers to recognize 2C intoxication and intervene promptly, and it underscores the importance of further research and public health efforts to address risks from rising recreational use of such substances.
Study at a glance
| Characteristics | Case study Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | 22-year-old female with bipolar I disorder |
| Intervention | medication stabilization |
| Keywords | 2c Emerging drugs Hallucinogenic Party drug Hallucinogens and psychedelics |
| Citations | 3 |
| Key finding | A patient with bipolar I disorder presented with visual hallucinations, euphoria, and tachycardia after using the 2C compound, requiring inpatient psychiatric stabilization. |
Abstract
"2C," formally known as 4-bromo-2,5-dimethoxyphenethylamine, is an illicit drug that combines elements of ketamine, MDMA (ecstasy), methamphetamine, cocaine, and opioids. This report highlights the emergence of 2C compounds, a new class of illicit drugs recognized for their distinctive blend of hallucinogenic and stimulant properties. We present the case of a 22-year-old female who was admitted to the psychiatric emergency department with a history of bipolar I disorder and recent use of various illicit substances, including the drug known as 2C. The patient exhibited symptoms such as visual hallucinations, euphoria, and an increased heart rate. Laboratory tests and toxicology screens were performed to confirm the presence of the components associated with the 2C compound. Her management involved admission to an acute inpatient psychiatric unit for medication stabilization. This case underscores the critical need for healthcare providers to recognize the signs and symptoms of 2C compound intoxication and to provide timely, appropriate intervention. With the rise in recreational use of such substances, further research and public health initiatives are essential to address the associated risks.